FDA Approves New Anti-Infective Combination for cIAI
The FDA approved aztreonam and avibactam (EMBLAVEO™, Abbvie) as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens. Read the announcement.
FDA Approves SC Infusion Device for Parkinson’s Disease
The FDA approved apomorphine hydrochloride injection (ONAPGO™, Supernus Pharmaceuticals) as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The wearable subcutaneous infusion device provides continuous treatment during the waking day for more consistent control of OFF time. ONAPGO will be available in the second quarter of 2025. Read the announcement.